Please login to the form below
Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio
Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST
Register now: http://bit.ly/2FnXsFx
When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.Join US Directors Tom Nolte and Melinda Shorr for this webinar which shows you how market research insights allow you to make confident go/no-go decisions in portfolio planning.
They will address:
Why portfolios need to adapt and change
Success today is not necessarily success tomorrow. Depth and diversification are essential to a strong portfolio - we explore the reasons why you need to actively plan for the future.
Considerations for Go/No-go research design for portfolio planning
We show you how to create an effective market research programme - what stakeholders needs to be involved in the planning process, what questions need to be asked and what methods can be used.
Determining value and magnitude metrics
We discuss the criteria by which additions to a pipeline fit into the key metrics – what value they bring to the portfolio and the size of that opportunity (magnitude). Conversely we will look at what the removal of an asset has on the overall portfolio.
Speed of decision-making
If agents are being developed in-house, evaluations can be made slowly and rigorously. When agents are being acquired, the decision to go or no-go often needs to be made quickly. We discuss the impact on market research design. Our presenters will also use a case study to demonstrate how market research insights support better decision-making on new agents in a portfolio.
Question and answer session
Following the presentation there will be a live Q&A where they will address any specific challenges you have encountered or concerns you may have about conducting portfolio analysis studies. We welcome you to submit your questions in advance when you register.
Register now: http://bit.ly/2FnXsFx
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Article: Creating truly effective communications - the impact of high speed, high octane messaging
- In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership
- Research Partnership makes two senior appointments to bolster its US and MedTech operations
- Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.
Research Partnership
- Case study: How segmentation of treaters guided a novel product launch in the allergy space
- Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment of Serious Allergic Reactions.
Research Partnership
- Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space
- Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.
Research Partnership
- Research Partnership wins prestigious 2023 BOBI Award
- We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.
Research Partnership
- Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market
- Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.
Research Partnership
